GlassScriptPhysician profile
Sheila M Krishna
NPI 1689817983
$6,893.17
in general payments reported to CMS, 2019-2025
29 companies · $724 in 2025
The $724 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $486 · 2021: $1,371 · 2022: $1,004 · 2023: $1,532 · 2024: $660 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400 · Education: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.61 |
| Education | $515.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,262.77 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,019.13 | 2019-2025 | |
| Incyte Corporation | $694.65 | 2021-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $371.60 | 2019-2023 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $364.93 | 2019-2023 | Dupixent |
| Genzyme Corporation | $351.75 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $324.44 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $308.22 | 2019-2024 | Sotyktu |
| Leo Pharma INC. | $306.02 | 2019-2023 | Adbry |
| Lilly USA, LLC | $285.10 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $264.11 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $234.77 | 2019-2025 | Ilumya |
| Ucb, INC. | $171.66 | 2021-2023 | Bimzelx, Cimzia |
| Amgen INC. | $166.76 | 2021-2023 | Otezla, Enbrel |
| Biofrontera INC. | $119.89 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $111.61 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $105.40 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $98.50 | 2023-2024 | Idacio |
| Verrica Pharmaceuticals INC. | $88.40 | 2025 | Ycanth |
| Galderma Laboratories, L.P. | $70.04 | 2019-2024 | |
| Prugen, INC. Pharmaceuticals | $35.00 | 2020 | |
| Dermavant Sciences, INC. | $31.52 | 2023 | Vtama |
| Celgene Corporation | $23.59 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.58 | 2023 | Spevigo |
| Organogenesis INC. | $18.55 | 2023 | Puraply |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.94 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.64 | 2023 | |
| Amneal Pharmaceuticals LLC | $14.60 | 2023 | Unithroid |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Krishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.